GSK To Pay $229M To Settle US Avandia Suits
GlaxoSmithKline PLC plans to pay $229 million to settle lawsuits relating to the development and marketing of controversial diabetes drug Avandia, along with a separate action in Louisiana, the research-based pharmaceutical...To view the full article, register now.
Already a subscriber? Click here to view full article